The clock is ticking on Eli Lilly’s big Alzheimer’s gamble; Pluristem reaches terms on $30M investment from China group

Eli Lilly’s huge solanezumab study is almost done. The pharma company noted this morning that the last patient visit has been recorded in its latest Phase III attempt to prove that the amyloid beta theory for Alzheimer’s is right. Lilly, of course, already had one failed Phase III effort on this drug. But they’re convinced that they can show cognitive benefits for patients with a mild form of the memory-wasting ailment. The data are due out before the end of the year, just weeks away.

Israel’s Pluristem Therapeutics has come to terms on a $30 million equity investment from China’s Innovative Medical Management Co. The money will be used to pay for pivotal work on the biotech’s cell therapies.

The gene therapy biotech Abeona Therapeutics $ABEO has won fast track status for ABO-12, its AAV gene therapy for subjects with MPS IIIA (Sanfilippo syndrome type A).

Adam Feuerstein’s “most reliable and skeptical healthcare investor source” is whispering into his ear about the upcoming fall that’s in store for Corbus Pharmaceuticals. TheStreet’s biotech writer isn’t identifying his top skeptic, but lays out why resunab is a big “nothing.” Data is due out in a matter of weeks.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->